31 May

Paper on adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis patients

A recent paper originating from ABIRISK research has been made available online. The paper presents an analysis of retrospective data in European cohort of RA patients treated with adalimumab or infliximab.

The paper with title “Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis” has been published in Seminars in Arthritis and Rheumatism:https://www.sciencedirect.com/science/article/pii/S0049017218301768

16 Nov

Stem cell-based model of the blood-brain barrier

A better understanding of the blood-brain barrier (BBB) is key for developing treatments for disease like MS and Alzheimer’s. In a collaboration with AstraZeneca, KTH, Karolinska Institute and University of Skövde  we recently published an article studying the use of human stem cells to generate in vitro models of the BBB. More specifically, we studied  the barrier properties and transcriptome of iPSC-derived models. Check out the full article published in Stem Cells (pubmed).


16 Aug

Immunogenicity risk in Multiple Sclerosis, paper in JCI Insight

In a recent paper, published in Journal of Clinical Investigation Insight, we describe a number of factors that influence the risk of immunogenicity responses (anti drug antibodies, ADA) in Multiple Sclerosis patients treated with Interferon beta (IFN-β). We found that NOTCH2 expression on CD14+ cells and increased frequency of proinflammatory monocyte subsets can be used as baseline predictors of neutralizing ADA  (nADA) in MS patients treated with IFN-β. Further investigation of NOTCH2 showed that nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-β administration.

Check out the full paper.


02 May

Dual objective: de-immunization and protein function

In a collaboration with the University of Tübingen and Harvard Medical School we have published  a paper on how to reduce immunogenicity and at the same time keep protein stability/function. The approach is based on multi-objective combinatorial optimisation and was tested on the C2 domain of Factor VIII.  For the full paper, go to Population-specific design of de-immunized protein biotherapeutics.

10 Feb

Regulatory B-cells, MTX and BAFFs role in TNF-a immunization

Recent findings describing the role of methotrexate and BAFF in preventing immunization to TNF-a inhibitors is presented at the 38th European Workshop on Rheumatlogy Research, EWRR 2018 Feb 22-14, Geneva Switzerland. This research was done in collaboration between SciCross and several partners from the ABIRISK consortium. Complete title: “Methotrexate and baff interaction prevents immunisation against TNF-Α inhibitors by increasing adenosine and regulatory B-cells”.


03 Apr

1st ABIRISK Drug Immunogenicity Conference

On April 1 the 1st ABIRISK Drug Immunogenicity Conference was held in Innsbruck, Austria. There were many highly interesting talks at this meeting, ranging from regulatory perspective by Amy Rosenberg FDA to a mathematical framework for prediction of therapeutic drug immunogenicity by Pfizer. SciCross presented an overview of the ABIRISK database, work that is done in collaboration with the IMI eTRIKS consortia.

The ABIRISK yearly general assembly and workpackage-specific meetings were held in Innsbruck the days before the conference. Here SciCross presented a tool for integration and analysis of data generated in a range of assays focused immunogenicity assessment of biopharmaceuticals. Please feel free to contact us for further discussions on this topic.